Related Experiment Video
Updated: Jul 22, 2025
07:53
Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
7.2K
Multidirectional characterization of cellular composition and spatial architecture in human multiple primary lung
Yawei Wang1,2,3, Di Chen2, Yu Liu1,2,4
1Department of Thoracic Surgery, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, 110042, Shenyang, China.
Cell Death & Disease
|July 24, 2023
Summary
Researchers discovered a new CLDN2-positive alveolar type II cell subtype in multiple primary lung cancers (MPLCs). This finding offers potential diagnostic markers and immunotherapeutic targets for MPLC treatment.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Multiple primary lung cancers (MPLCs) present significant clinical challenges in diagnosis and treatment.
- Understanding the cellular and spatial characteristics of MPLCs is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To elucidate the cellular and spatial architecture of multiple primary lung cancers (MPLCs).
- To identify novel cellular subtypes and potential therapeutic targets within MPLCs.
Main Methods:
- Single-cell RNA sequencing was employed to analyze cellular composition.
- Spatial transcriptomics was utilized to map cellular distribution and interactions within tumor tissues.
Main Results:
- A novel epithelial cell subtype, CLDN2-positive alveolar type II (AT2) cells, was identified and found to be enriched in MPLCs.
- CLDN2 protein expression can differentiate MPLCs from intrapulmonary metastasis and solitary lung cancer.
- High expression of the cell surface receptor TNFRSF18/GITR on T cells suggests its potential as an immunotherapeutic target.
- Significant inter-lesion heterogeneity was observed within MPLCs.
Conclusions:
- The identified CLDN2+ AT2 cells play a role in cellular communication and spatial aggregation in MPLCs.
- CLDN2 protein serves as a potential diagnostic biomarker for distinguishing MPLCs.
- TNFRSF18 represents a promising immunotherapeutic target for MPLC treatment.
- These findings enhance the understanding of MPLC biology and offer new avenues for diagnosis and therapy.
